by Maria Zannes | Jul 23, 2018 | Press Releases
JULY 17, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has commenced its test validation trial for CyPath® Lung, an advanced flow cytometry test for the early detection of lung cancer. Recruitment is...
by Maria Zannes | May 18, 2018 | News
MAY 15, 2018 As published in Xconomy Texas By David Holley (SAN ANTONIO, TX) bioAffinity, the maker of a cancer diagnostic test, has added Peter Knight, who was the chief of staff for Al Gore when he was in Congress, to its board of directors and is in the process of...
by Maria Zannes | May 18, 2018 | Press Releases
MAY 14, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Peter S. Knight, founding partner of Generation Investment Management, to its Board of...
by Maria Zannes | Mar 15, 2018 | News
MARCH 1, 2018 As published in the San Antonio Business Journal By W. Scott Bailey San Antonio-based bioAffinity Technologies has been approved for membership in the Early Detection Research Network, an initiative of the National Cancer Institute. The approval gives...
by Maria Zannes | Mar 15, 2018 | Press Releases
FEBRUARY 28, 2018 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced it had been approved for membership in the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI). EDRN...
